Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Metabolic Disorders Clinical Trials Commercial

Phase III Data Put Zealand's Dasiglucagon On Track, But Behind Others, For Hypoglycemia Rescue

  • Analysis

Executive Summary

Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.

You may also be interested in...



Zealand Set To Take On Lilly After Zegalogue US Approval

Despite being third to market behind Lilly’s Baqsimi and Xeris’s Gvoke to treat emergency episodes of hypoglycemia, Zealand is confident of a successful US launch for Zegalogue (dasiglucagon).

Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

The latest drug development news and highlights from our US FDA Performance Tracker.

Zealand Rushes Out Good Safety News On Phase III Dasiglucagon Rescue Pen

Early results confirm dasiglucagon's safety profile with no treatment-induced or treatment-boosted anti-drug antibodies.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Metabolic Disorders Clinical Trials Commercial
UsernamePublicRestriction

Register

SC123872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By